الفهرس | Only 14 pages are availabe for public view |
Abstract Diabetes mellitus is a group of metabolic diseases -multi-systemic disorder- characterized by hyperglycemia resulting from defects in insulin secretion. The therapeutic treatment with bone marrow mesenchymal stem cells “BM-MSCs” has a promising value in the management of kidney, liver and pancreatic degeneration. Fifty male rats were used in this experiment; 5 rats as a source of BM-MSCs, 5 rats (STZ-diabetic) as the cell tracking and the other 40 rats were randomly assigned into 4 equal groups; normal control (I), stem cell (II), untreated diabetic (III), and treated diabetic (BM-MSCs) (IV). To induce DM, rats were intraperitoneally injected single dose of streptozotocin (STZ) (55 mg/kg BW). The BM-MSCs were collected from 10 rats’ bone marrow, cultured, characterized using flow cytometry analysis and labeled with Qtracker 655 cell labeling. BM-MSCs were transplanted in treated diabetic at the 7th day of STZ injection. Rats were euthanized 4 weeks after STZ injection. Blood samples were collected at the end of experiment (4th week of BM-MSCs transplantation). The pancreas, kidney and liver tissues were collected. Hemogram, biochemical parameters (liver & Kidney function tests), insulin gene expression and histopathological examination of pancreas, liver and kidney, were performed for all experimental groups. Untreated diabetic group showed significant disturbances in liver, kidney and pancreatic functions with excessive production of inflammatory cytokine (TNF-α) in kidney tissues and increased oxidative stress in liver tissues. The BM-MSCs treated diabetic group showed significant improvement in organs functions, insulin gene expression as well as hematological and histopathological examinations. In conclusion, treatment with BM-MSCs in diabetic rats improved the diabetic profile and ameliorated some of its complications. |